

Press Release

Notice Regarding Revision of Financial Forecasts for FY2025

TOKYO, October 30, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced revisions to its consolidated financial forecast for the fiscal year ending March 31, 2026 (FY2025), originally announced on April 25, 2025 (Core basis and Full basis), as follows.

1. Revision of Financial Forecasts:

<Core basis>

(Millions of yen)

	Revenue	Core operating profit	Core Profit for the year	Basic core earnings per share (yen)
Previous forecast(A)	1,930,000	410,000	304,000	169.80
Revised forecast(B)	2,030,000	490,000	365,000	203.79
Change(B-A)	100,000	80,000	61,000	-
Change(%)	5.2	19.5	20.1	-
(Ref.) Actual fiscal year 2024	1,912,323	392,435	295,682	165.17

<Full basis>

(Millions of yen)

	Revenue	Operating profit	Profit before tax	Profit for the year	Profit attributable to owners of the parent	Basic earnings per share (yen)
Previous forecast(A)	1,930,000	160,000	150,000	130,000	130,000	72.61
Revised forecast(B)	2,030,000	240,000	230,000	180,000	180,000	100.50
Change(B-A)	100,000	80,000	80,000	50,000	50,000	-
Change(%)	5.2	50.0	53.3	38.5	38.5	-
(Ref.) Actual fiscal year 2024	1,912,323	41,039	31,237	50,747	50,747	28.35

2. Reason for Revision:

Among our Strategic Brands, the strong growth of VYLOY™ (zolbetuximab) for gastric and gastroesophageal junction adenocarcinoma and PADCEV™ (enfortumab vedotin) for urothelial cancer has significantly driven our performance. Additionally, XTANDI™ (enzalutamide) for prostate cancer has also experienced sales growth across all regions, contributing to a positive global trend. As a result, our revenue has steadily increased. Furthermore, the impact of cost management from our company-wide initiative, Sustainable Margin Transformation, which focuses on cost optimization, is also expected to contribute positively to our performance.

About Astellas

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Communications and Investor Relations
+81-3-3244-3201